ArticleVeterinary medicine and science2025
Structural, Functional and Inhibitory Annotations of Lumpy Skin Disease Virus Hypothetical Protein LSDV004: An In-Silico Study.
Article in Veterinary medicine and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research Review on Inhibitors of Lumpy Skin Disease Virus: From Biological Characteristics, Drug Repurposing, to Computer-Aided Drug Design.International journal of microbiology · 2026Review
- Lumpy Skin Disease Virus Pathogenesis: Viral Protein Functions and Comparative Insights from Vaccinia Virus.Animals : an open access journal from MDPI · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lumpy skin disease virus (LSDV) is the etiological agent of lumpy skin disease (LSD), predominantly afflicting cattle populations and posing significant economic implications to the livestock industry. Despite the comprehensive genome sequencing of LSDV, several hypothetical genes with unknown functions remain, potentially playing pivotal roles in disease pathogenesis and serving as targets for drug discovery. This study aimed to explore the LSDV004 gene by predicting its key properties, structure, functions and potential inhibitors using bioinformatic tools. Physiochemical analysis using ExPASy ProtParam indicates LSDV004 is a stable protein with an instability index below 40, suggesting structural stability. Secondary structure analysis via SOPMA identifies the random coil as the predominant structural element, covering 50.88% of residues, followed by extended strands (36.84%). The tertiary structure predicted and refined using SWISS-MODEL and GalaxyRefine respectively, > 90% of residues in the favoured region of the Ramachandran plot, according to PROCHECK validation. Functional prediction highlights structural similarities with the Swinepox virus C2 and suggests potential involvement in pathways such as negative regulation of gene expression, as indicated by gene ontology (GO) analysis using I-TASSER. Moreover, the GO analysis indicates functional similarity with anti-apoptotic protein Bcl-2-like protein 1 (PDB ID: 1LXL). Molecular docking studies with HDOCK reveal pelcitoclax as exhibiting better docking characteristics compared to other Bcl-2 inhibitors. However, it's important to note that these predictions require validation through wet laboratory experiments to confirm the LSV004 protein's structural, functional and inhibitory properties. These findings suggest LSDV004's role in LSD pathogenesis and its potential as a drug target and also highlight areas for further experimental studies to confirm its function, supporting efforts toward effective treatments and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.